The latest update is out from Avenue Therapeutics (ATXI).
At the 2024 Annual Meeting of a company conducted virtually, stockholders approved three key proposals: the election of six directors for the upcoming year, the ratification of KPMG LLP as the independent accounting firm for the fiscal year, and an amendment to the 2015 Plan. The election saw a majority of votes cast in favor of all director nominees, and both the ratification and the amendment passed with significant support, reflecting stockholder confidence in the company’s governance and strategic direction.
For a thorough assessment of ATXI stock, go to TipRanks’ Stock Analysis page.
